Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
about
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriersCoregistered photoacoustic and ultrasound imaging and classification of ovarian cancer: ex vivo and in vivo studiesThe effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic reviewPathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.Current concepts in premature ovarian insufficiency.Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers.Hormone replacement therapy in young women with surgical primary ovarian insufficiency.Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future.Fertility preservation in gynaecologic cancers.Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect
P2860
Q27003935-2103679C-5C2C-43DF-8751-178185C26FCDQ30358477-2C376BB2-3940-4E93-B663-C2A5A7CB7376Q36315490-E7D0BCFC-6B64-4853-B700-FE7CE3C61EA0Q37512375-DD614A6F-37B1-44C5-8F0A-A44775307D41Q38380077-FF3ED114-9436-4B01-9851-590BDBFEF1D2Q38732720-58BF1607-E4F7-414E-82FB-EB7F0FDC45ECQ38759806-AE42E6F2-3ACE-4B80-BD32-92030E7A6C33Q38993952-BA12B039-A2CF-4437-9700-151826843F2BQ39027448-8E935C45-80E1-4D20-B6E3-0BB6B5C58308Q41161920-755B6FFE-1DBE-4CE7-9EF4-DE87E7603EC2Q46581570-2956A314-AD3A-429C-9DD1-71F8E8264277Q47762116-6F101E87-CD91-4A27-98E7-6BE6ED93E1FFQ48082724-D9DEBA13-84FB-4968-B5AD-61E35C8CA203Q49957633-78E26AB3-D02E-41D5-AFA4-83964CE1155FQ53757323-0C48F8BF-EAC1-4380-B6C1-FE5C45ECBA32Q57137351-224D9766-6E9E-4F64-8B15-72C005AC1A74
P2860
Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
@en
type
label
Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
@en
prefLabel
Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
@en
P50
P1433
P1476
Hormone therapy in oophorectomized BRCA1/2 mutation carriers
@en
P2093
Perluigi Bendetti Panici
Roberta Iadarola
P304
P356
10.1097/GME.0000000000000126
P407
P577
2014-07-01T00:00:00Z